Evaluation of annexin A5 as a biomarker for Alzheimer's disease and dementia with lewy bodies
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Alzheimer's disease (AD) differs from other forms of dementia in its relation to amyloid beta peptide (Aβ42). Using a cell culture model we previously identified annexin A5, a Ca(2+), and phospholipid binding protein, as an AD biomarker. Plasma level of annexin A5 was significantly higher in AD patients compared to that in a control group. On the other hand, AD has been identified to share a number of clinical and pathological features with Dementia with Lewy bodies (DLB). The present study was done to examine whether or not plasma annexin A5 is a specific marker for AD, when being compared with the levels of DLB patients. As Apolipoprotein E (ApoE) gene subtype ε4 (ApoE-ε4) has been noticed as the probable genetic factor for AD, we also examined and compared ApoE genotype in both AD and DLB. METHODS: Blood samples were obtained from 150 patients with AD (aged 77.6 ± 6.5 years), 50 patients of DLB (79.4 ± 5.0) and 279 community-dwelling healthy elderly individuals of comparable age and sex (75.6 ± 8.1). All AD patients met NINCDS-ADRDA criteria and all DLB patients were diagnosed as probable DLB according to the latest consensus diagnostic criteria. Quantification was done using the Chemiluminescent Enzyme Immunoassay (CLEIA) Technique (SphereLight assay) using the monoclonal antibodies against annexin A5. DNA genotyping of ApoE was performed by distinguishing unique combinations of Hha1 fragments of PCR-amplified genomic DNA products. RESULTS: The plasma level of annexin A5 was significantly higher in AD patients than in the healthy individuals (control) (P < 0.0001). The plasma annexin A5 level was also significantly higher in DLB patients than in the control group (P < 0.0001). From the ROC curves with plasma annexin A5 concentrations, the mean areas under the curve were 0.863 and 0.838 for the AD/control and DLB/control, respectively. The rate of ApoE4 carrier status and the frequency of the ε4 allele were significantly higher in AD or DLB than in control and there was no significant difference between AD and DLB. CONCLUSIONS: These results suggest that both annexin A5 and ApoE4 are common markers for AD and DLB.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The role of apolipoprotein E in Alzheimer's disease
Kim, J., Basak, J. M., & Holtzman, D. M. (2009) · Neuron · doi:10.1016/j.neuron.2009.06.026 · Cited by 1,661 · cited 1×
“ApoE ε4 is associated with an increased risk for AD with an earlier age of disease onset (Kim et al., 2009).”
BackgroundLinking lipids to Alzheimer's disease: cholesterol and beyond
Di Paolo, G., & Kim, T.-W. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3012 · Cited by 972
Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses
Bertram, L., & Tanzi, R. E. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2494 · Cited by 747 · cited 1×
“The ε4 allele of the ApoE gene was identified as the strongest genetic risk factor for AD (Bertram and Tanzi, 2008).”
BackgroundApolipoprotein E structure: insights into function
Hatters, D. M., Peters-Libeu, C. A., & Weisgraber, K. H. (2006) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2006.06.008 · Cited by 583 · cited 1×
“ApoE, which is a major component of lipoproteins, is comprised of 299 amino acid residues and plays a role in the metabolism and redistribution of cholesterol (Hatters et al., 2006).”
BackgroundEvaluation of CSF-tau and CSF-Aβ42 as diagnostic markers for Alzheimer disease in clinical practice
Andreasen, N., Minthon, L., Davidsson, P., Vanmechelen, E., Vanderstichele, H., Winblad, B., & Blennow, K. (2001) · Archives of Neurology · doi:10.1001/archneur.58.3.373 · Cited by 573
Mollenhauer, B., Cullen, V., Kahn, I., Krastins, B., Outeiro, T. F., Pepivani, I., Ng, J., Schulz-Schaeffer, W., Kretzschmar, H. A., McLean, P. J., et al. (2008) · Experimental Neurology · doi:10.1016/j.expneurol.2008.06.004 · Cited by 382 · cited 1×
“Whereas some groups show a decrease in the total concentration of CSF α-synuclein in DLB in comparison to other dementias (Mollenhauer et al., 2008; Kasuga et al., 2010), other groups do not find the significant difference for DLB (Spies et al., 1998; Noguchi-Shinohara et al., 2009).”
ResultDong, L. M., Wilson, C., Wardell, M. R., Simmons, T., Mahley, R. W., Weisgraber, K. H., & Agard, D. A. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)31797-0 · Cited by 320
Human Apolipoprotein E4 Domain Interaction
Dong, L.-M., & Weisgraber, K. H. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.32.19053 · Cited by 318
Lalazar (1989) · doi:10.1016/s0021-9258(18)81806-3 · Cited by 238
Cited by
Hales, C. M., Dammer, E. B., Deng, Q., Duong, D. M., Gearing, M., Troncoso, J. C., Thambisetty, M., Lah, J. J., Shulman, J. M., Levey, A. I., et al. (2016) · PROTEOMICS · doi:10.1002/pmic.201600057 · Cited by 99
“This protein was decreased specifically in the CSF-producing choroid plexus in early AD stages [55], but increased in blood serum of AD patients [56].”
BackgroundExpression of Regulatory Proteins in Choroid Plexus Changes in Early Stages of Alzheimer Disease
Krzyzanowska, A., García-Consuegra, I., Pascual, C., Antequera, D., Ferrer, I., & Carro, E. (2015) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0000000000000181 · Cited by 42
“To date, plasma annexin V levels have been proposed as a possible biomarker for AD and dementia with Lewy bodies (39).”
BackgroundHuman amygdala involvement in Alzheimer's disease revealed by stereological and dia‐PASEF analysis
Gonzalez‐Rodriguez, M., Villar‐Conde, S., Astillero‐Lopez, V., Villanueva‐Anguita, P., Ubeda‐Banon, I., Flores‐Cuadrado, A., Martinez‐Marcos, A., & Saiz‐Sanchez, D. (2023) · Brain Pathology · doi:10.1111/bpa.13180 · Cited by 36
“Furthermore, ANXA5 has been evaluated as a potential biomarker for AD since its plasma levels are increased in AD [59] and as a potential candidate for monitoring the progression of the disease [60].”
Background
Metadata
- Authors
- Sohma, H., Imai, S.-I., Takei, N., Honda, H., Matsumoto, K., Utsumi, K., Matsuki, K., Hashimoto, E., Saito, T., & Kokai, Y.
- Venue
- Frontiers in Aging Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2013
- Volume
- 5
- Pages
- 15-15
- ISSN
- 1663-4365 (ISSN-L)
- OpenAlex
- W2139711289
- Cited by
- 36
- References
- 9
- FWCI
- 2.13
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Evaluation of annexin A5 as a biomarker for Alzheimer's disease and dementia with lewy bodies. https://app.cochat.ai/papers/10.3389/fnagi.2013.00015
- The paper
- Sohma, H., Imai, S.-I., Takei, N., Honda, H., Matsumoto, K., Utsumi, K., Matsuki, K., Hashimoto, E., Saito, T., & Kokai, Y. (2013). Evaluation of annexin A5 as a biomarker for Alzheimer's disease and dementia with lewy bodies. Frontiers in Aging Neuroscience. https://doi.org/10.3389/fnagi.2013.00015
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.